Highly multiplexed, quantitative protein biomarker profiling (hmqPro)

Informacje na temat projektu

hmqPro

Identyfikator umowy o grant: 101069454

DOI

10.3030/101069454

Projekt został zamknięty

Data podpisania przez KE 16 Maja 2022

Data rozpoczęcia 1 Lipca 2022

Data zakończenia 31 Grudnia 2023

Finansowanie w ramach

• European Research Council (ERC)

Koszt całkowity

Brak danych

Wkład UE

€ 150 000,00

Koordynowany przez

KAROLINSKA INSTITUTET
Sweden

Periodic Reporting for period 1 - hmqPro (Highly multiplexed, quantitative protein biomarker profiling (hmqPro))

Okres sprawozdawczy: 2022-07-01 do 2023-12-31

Podsumowanie kontekstu i ogólnych celów projektu

The project will develop a multipurpose, highly multiplexed, quantitative protein profiling (hmqPro) platform that can be adapted to a wide range of applications, particularly biomarker discovery. Biomarkers are a 43 Billion USD market spanning applications in diagnostics, drug discovery & development, personalized medicine, disease risk assessment. The project aimed to develop a new quantitative protein profiling platform without the need for specialized laboratory equipment that will have the capacity to impact the biomarker discovery market by combining unique flexibility with high-throughput.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

In an academic-commercial partnership between Karolinska Institutet and Epigenica AB, technological foundations were laid for a method comprising antibody-based quantitation of multiple proteins in a large number of samples. Various chemistries and molecular biology steps in the procedure required extensive optimization and trouble-shooting. Alternative quantitation strategies on solid support and in solution were piloted. The outcome of the project is a optimized reagents design and workflow that we will further develop into the intended highly multiplexed protein profiling method in the future.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

In parallel with validating the fundamentals of the intended assay platform, we have performed market analysis focussing specifically on diagnostic applications of protein profiling methods in liquid biopsies.
Following up on the results and insights gained in this project, we will continue the product development trajectory, first completing development of the assay platform, then performing a variety of validations on different biological source material and protein targets. Ultimately, the novel hmqPRO assay platform will join Epigenica AB's product development program in form of kit and service offerings.